ABSTRACf. Synthetic pulmonary surfactants consisting of mixtures of phospholipids with synthetic peptides based on the amino acid sequence of human surfactant apoprotein SP-B were prepared. These surfactants were analyzed for their ability to lower surface tension on a pulsating bubble surfactometer and for their capacity to improve lung compliance and increase alveolar expansion in a fetal rabbit model of surfactant deficiency. The data demonstrate that several peptides, ranging from 17 to 45 residues in length, matching the carboxy-terminal sequence of the SP-B protein, when appropriately recombined with the phospholipids dipalmitoylphosphatidylcholine and phosphatidylglycerol (3:1), are capable of producing a synthetic surfactant with biophysical and biologicactivity approaching that of human surfactant derived from amniotic fluid. (Pediatr Res 29: 460-465, 1991) Abbreviations DPPC, dipalmitoylphosphatidylcholine lA, iodoacetic acid PG, phosphatidylglycerol PL, phospholipid SP, surfactant protein or swine, or synthetic lipids, generally in combination with SPBand SP-C (7, 10, 11, 13-15, 17-19, 21-23, 27), are being evaluated for their potential use in surfactant replacement therapies.
or swine, or synthetic lipids, generally in combination with SPBand SP-C (7, 10, 11, 13-15, 17-19, 21-23, 27) , are being evaluated for their potential use in surfactant replacement therapies.
Our previous studies (10) and those of Curstedt et al. (2) , and Yu and Possmayer (19) , suggested that when recombined with PL, SP-B resulted in greater surface tension lowering and biologic activity than did SP-C. For this reason, we decided to focus our attention on this protein. SP-B, also called SP-18 (4, 10) , SPL(Phe) (3), PSP-B (5), and SAP-6-14 (7, 16, 17, 23) , has been shown to be a disulfide-linked dimer of two identical polypeptides of approximately 9000 D having an amino terminal sequence of phe-pro-ile-pro-leu-pro-tyr-(human) (3, 5, 10) . Data based on amino acid compositions (10) and fast atom bombardment mass spectroscopy (unpublished observations) have led us to conclude that human SP-B is 80-81 residues in length. The sequence is shown in Figure I .
To investigate the mechanisms by which SP-B protein augments the surfactant capacity of PL, peptides were synthesized that conform to portions of the native sequence of this protein. These peptides could be combined with PL to reconstitute the biophysical and biologic activities of natural surfactant. We report here the results of studies, using the pulsating bubble surfactometer to measure the capacity of these synthetic surfactants to lower surface tension at an air/liquid interface and the fetal rabbit model to determine their ability to increase lung compliance and alveolar expansion.
MATERIALS AND METHODS

Preparation ofpurified SP-B monomer, dimer, and oligomers.
SP-B was isolated from human amniotic fluid surfactant ad escribed previously (10) . One hundred J.Lg of SP-B, in a volume of 206 J.LL methanol, were incubated with 5.14 mg DTT (Sigma Chemical Co, St. Louis, MO) in 17 J.LL methanol, for 1 h at 37°C. Analysis of 2 J.LL on SDS-PAGE showed the SP-B to be approximately 70% reduced as noted by a shift in band position from 18000 D to approximately 9000 D. The SP-B/DTT mixture was allowed to incubate an additional 30 min at 3TC and overnighi at room temperature under N z . A 10-J.LL aliquot was rernovec and 20 J.LL containing 40 J.LCi of 3H_IA (ICN Radiochemicals Irvine, CA) in water were added. After 30 min of incubation a1 37°C, this aliquot was added back to the SP-B/DTT mixture along with 27.74 mg unlabeled IA in 25 J.LL water. Alkylatior was allowed to proceed for I h at 3TC. Chloroform and HC were added to make the final mixture chloroform/methanol, 1:I +5% 0.1 N HCl. The sample was then loaded onto a 1 x 40 err 460
The presence of two hydrophobic, low molecular weight apoproteins in mammalian pulmonary surfactant has been shown (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , and cDNA clones have been isolated that predict the amino acid sequences of their precursor molecules (3-5, 10, 15) . The importance of these apoproteins, termed SP-B and SP-C (20) in the ability of natural or synthetic surfactants to be able to reduce surface tension at the epithelial air/liquid interface in the lung has been the subject of several recent papers (2, 7, 10, 11, (13) (14) (15) (17) (18) (19) (21) (22) (23) . Human surfactant isolated from term amniotic fluid (24) (25) (26) , as well as heterologous surfactants consisting of lung mince or airway lavage lipid extracts from calves Sephadex LH-60 (Pharmacia Fine Chemicals, Uppsala, Sweden) column. The column was run at a flow rate of 2.5 mL/h using the acidified chloroform/methanol buffer, and fractions of 0.5 mL were collected.
Fractions were analyzed for the presence of 3H, unreacted DTT, lA, and SP-B proteins (by SDS-PAGE). Monomer, dimer, and higher molecular weight oligomers, all carrying a trace amount of 3H, were found in fractions 11-19, well before excess DTT, DTT-IA, and breakdown products of IA were eluted in fractions 32-60. Figure 2 shows the molecular weight characteristics of the various SP-B forms separated on this column. Pools were made of oligomer/dimer (fractions II and 12), dimer (fractions 13 and 14) , and monomer (fractions [16] [17] [18] [19] . The pools were dried under N 2 , lyophilized for I h, redissolved in 500~L methanol, and quantitated by amino acid compositional analysis.
Peptide synthesis. Peptides were prepared by solid-phase synthesis according to the methods of Houghten (28) or Merrifield (29) . In the latter case, an Applied Biosystems (Foster City, CA) 430A or 431A peptide synthesizer was used. Four equivalents of amino acid derivative were activated with equimolar l-hydroxybenzotriazole and dicyclohexylcarbodiimide. This resulting ester was reacted with the peptide-phenylacetamidornethyl resin for 60 min to effect peptide bond formation. Aspartic acid, glutamic acid, threonine, and serine were protected as the benzyl esters, arginine by the tosyl group, tyrosine as the orthobrornobenzyloxycarbonyl ester, and cysteine as the methylbenzyl ester. The sulfur group of methionine was not protected during peptide synthesis. The trifluoroacetic acid-treated peptide resins were cleaved by the hydrogen fluoride/anisole procedure (30, 31) at -4°C for I h. The peptides were extracted from the resin matrix using 70% acetic acid/water or neat trifluoroacetic acid, diluted with water, and lyophilized. The crude product (typically 300-500 mg) was purified on a Waters Auto 500 preparative HPLC (Waters Associates, Milford, MA) fitted with a 2-inch PrepPak cartridge packed with Vydac CI8 30-llm particles with 300-A pore size (Western Analytical Products, Temecula, CA). These peptides were eluted off the column with a gradient between water and acetonitrile, both containing 0.1 % trifluoroacetic acid (vol/vol). The purified products were characterized by amino acid analysis, peptide content determination, analytical HPLC analysis (Vydac C 18, 5-llm particles with 300-A pore size, 4.6 x 250 mm) and/or fast atom bombardment mass spectroscopy analysis. Peptides were stored in a vacuum desiccator at room temperature.
Preparation of synthetic surfactants. All PL were purchased from Avanti Polar-Lipids, Inc. (Pelham, AL). t.-c-dipalmitoyl lecithin (DPPC) and PG (egg) were mixed in chloroform in a 3: I (wt/wt) ratio.
Peptide in chloroform/methanol (generally 50% chloroform, 50% methanol) was added to PL in chloroform at a ratio of I: 10 (wt/wt) unless stated otherwise. The mixture was incubated at 43°C for 10 min and then dried under N 2 • In most cases, the sample was further dried by a IS-min exposure to vacuum. Water was then added in an amount calculated to equal 90% of the volume necessary to give a final lipid concentration of 4, 10, or 20 mg/rnl., The mixture was incubated for I h at 43°C with periodic vortexing. A volume of 6% NaCi equal to 10% of the volume necessary to give the desired PL concentration was added, and the mixture was incubated an additional 10 min at 43°C. In some cases, the final mixture was subjected to three cycles of freezing and thawing.
Surfactant activity assays. Methods for the assessment of surfactant activity measured in vitro using the pulsating bubble surfactometer and in vivo by the generation of static pressurevolume curves in 27-d gestation fetal rabbits after treatment with surfactant have both been described in detail previously (32) . The current study also incorporates the use of dynamic pulmonary compliance measurements in the fetal rabbit model. Briefly, the technique involves the placement of the tracheostomized fetuses, after the administration of the test surfactants, into a 12-place, thermostated plethysmograph, where they are ventilated in parallel for up to 60 min at a peak inspiratory pressure of 25 em H 2 0 , and a positive end expiratory pressure of 0-3 em H 2 0 , using an inspiratory time of 0.5 s (30 breaths/min). Air flow and airway pressure were measured at 10-min intervals with a pressure transducer (Celesco, Canoga Park, CA) and the signals were digitally analogued into a microcomputer for calculation of dynamic compliance and pulmonary resistance. Synthetic surfactant samples for in vivo assays were prepared as described above and instilled according to one of the following two protocols: 1) For static pressure/volume experiments, 2 mg of PL ± peptide (or 2 mg natural human surfactant) in a volume of 0.1 mL were injected into the trachea and the animal immediately connected to the ventilator. 2) For dynamic compliance experiments, 0.2 mL of 20 mg/rnl. surfactant, followed by 0.15 mL air, 0.1 mL physiologic saline, and 0.3 mL air were injected from one syringe into the trachea. Two subsequent aliquots of 0.3 mL air were given before the animal was connected to the ventilator.
SDS-gel electrophoresis. PAGE in 16% polyacrylamide plus SDS was performed in 3 x 7 em mini-gels according to the method of Laemmli (33) . Methods of fixation and staining have been described previously (10) . Hydrophobic moments. Hydrophobic moments for various peptides were calculated according to the method of Eisenberg (34) .
RESULTS
SP-S dimer versus monomer.
To determine whether the monomeric SP-B polypeptide would possess activity, a study was designed to compare activities of dimeric and monomeric SP-B. Native SP-B was subjected to reduction and alkylation, which typically results in reduction of 70-80% of the protein, and separated by chromatography on LH-60 Sephadex into pools containing monomer, dimer, and a mixture of dimer plus higher molecular weight oligomers. These polypeptides, as well as untreated SP-B, were then combined with the phospholipids DPPC and PG at a weight ratio of 0.5% protein to PL. The mixtures were analyzed for their ability to lower the surface tension on the pulsating bubble surfacto meter. The results are shown in Table I . At IS s, the surfactant mixture containing monomer was slightly less active than those containing dimer or dimer plus oligomers; at the other time points, all three show comparable activities. Interestingly, the dimer that had been exposed to the reduction and alkylation procedure was significantly less active than native SP-B, even though native SP-B is >90% dimer. This suggests that alkylation of free sulfhydryl groups may inhibit activity. More 3H-IA was bound per Ilg of monomer than dimer or oligomer (279 cpm/Ilg monomer, 214 cpm/Ilg dimer, and 198 This report describes the use ofsynthetic peptides derived from the sequence of human pulmonary surfactant apoprotein SP-B DISCUSSION mine if there was any correlation between the amphiphilicity of a peptide and its activity, hydrophobic moments were calculated for the series of 15-residue peptides taken from throughout the SP-B sequence. These are shown in the right-hand column of Table 2 . There was no consistent correlation between hydrophobic moments and activity.
SP-B
Relationship of SP-B polypeptide size and activity. Because it was apparent that multiple peptides were able to partially reconstitute surfactant activity, we next examined the potential relationship between the length of the SP-B peptide and its capacity to induce surfactant activity. A series of peptides of increasing length matching the carboxy-terminal end ofSP-B were prepared (Fig. 3) . Each was combined with PL to produce a synthetic surfactant and tested in the pulsating bubble surfacto meter. The results are shown in Table 3 . A minimal length of at least 17 residues, represented by pM-80, appeared to be necessary to attain surface tensions below IO dynes-em." by 5 min. An additional series of peptides all having the carboxy-terminal sequence of SP-B ending at residue 81 showed similar results.
To determine if smaller amounts of larger peptides would be effective, the eight peptides shown in Figure 3 were tested at concentrations less than 10% relative to PL. The results, shown as the average surface tension at minimal bubble radius at 5 min, are tabulated in Table 4 . Although 3% of the 17-residue peptide reduced the surface tension to 1.6 dynes-cm", even 10% of the slightly smaller 15-residue peptide did not reduce the surface tension below 10 dynes-cm:'. The data suggest that, in this series of peptides, the length and/or the specific residues included in the peptide are more critical to consequent activity than is its relative concentration (at least within the range 1-10%).
Various other synthetic peptides based on the sequence ofSP-B were prepared, mixed with PL, and analyzed on the pulsating bubble surfactometer for biophysical activity. All showed at least moderate activity (a reduction of surface tension to less than 20 dynes/em by 5 min) when compared with PL alone. The peptides tested were: pI2-41, pI6-41, p46-76, p51-n, p51-76, p51-77, p53-77, p53-78, p54-n, and p54-76.
A number of peptides unrelated to SP-B were also tested for their ability to lower surface tension when mixed with PL. A wide range of activities was found. Those studies, including an analysis of the characteristics necessary for a peptide to impart reasonable surfactant activity to PL, will be reported separately.
Synthetic peptide surfactants-s-in vivo assays. The biologic activities of several surfactant mixtures prepared with synthetic peptides derived from the sequence of SP-B were determined in the fetal rabbit model. Static inflation and deflation pulmonary pressure-volume curves were obtained after 30 min of ventilation after the instillation of the surfactants. Figure 4 shows the results obtained with synthetic surfactants prepared with 1.5% peptide 1-15, 52-81, or 66-81. Surfactants incorporating peptides 52-81 and 66-81 resulted in an increase in lung compliance compared with PL alone, whereas the incorporation of 1.5% peptide 1-15 did not increase compliance.
Dynamic compliance measurements allow one to follow the improvement in compliance over time and were therefore used to analyze the efficacy of many of the synthetic peptide surfactants. Figure 5 shows the computer-generated tracings of dynamic compliance measurements for selected surfactants as a function of time. Natural human surfactant and PL alone are shown as positive and negative controls, respectively. It can be readily seen that all of these synthetic peptide surfactants were able to significantly increase compliance over the values seen with PL alone. It is interesting to note that the kinetics of the synthetic surfactant compliance increases appear to be slower than that seen with natural human surfactant. cpm/sg dimer/oligorner), perhaps explaining why its activity may be slightly lower at 15 s. It is clear from these data, however, that SP-B monomer is able to cause a significant decrease in surface tension when added to PL. Synthetic peptide surfaaants-i-in vitro assays. To investigate the mechanism by which SP-B protein augments the surfactant capacity of PL, eight peptides, matching sequential overlapping regions ofSP-B, were prepared by simultaneous multiple-peptide solid phase synthesis. The peptides were dissolved or suspended in chloroform/methanol, I: I, and combined with the phospholipids DPPC and PG (3:I). The various surfactant mixtures were then assayed for biophysical activity in the pulsating bubble surfactometer. The results are shown in Table 2 . All of the peptides tested were able to reduce significantly the surface tension at minimal bubble radius from the values of >49. Relationship ofpeptide amphiphilicity and activity. To deter- t PL, phospholipids at 10 mg/rnl., § Peptides were 10% by weight compared with PL.
* Pulsation of 20 cycles/min started lOs after bubble formation. All values are in dynes-em." and are the mean ± SEM of at least three determinations. 
Deflation Inflation
• PL + 1.5% p52-S1 (n~4) o PL + 1.5% p66-S1 (n~4) Data are expressed as the mean of four animals ± I SD.
to repeat those studies in the absence of alkylating agents were not successful due to the propensity of the single chains to redimerize.
The ability to show activity in the pulsating bubble assay of SP-B monomer after recombination with PL led to the question of whether all 80 or 81 residues were required for this activity. Our initial screening of IS-residue overlapping segments of the molecule showed that biophysical activity could be obtained with most peptide segments ( Table 2 ). In studies to be reported separately, we have shown that amino acid sequences unrelated to the SP-B sequence, but consisting of various combinations of hydrophobic and hydrophilic residues, can also mimic this activity when appropriately recombined with PL. In a recent publication, Venkitaraman et at. (35) showed that mixtures of DPPC or DPPCjPG (8:2) with polyleucine or polyphenylalanine are able to lower surface tension significantly, whereas the more hydrophilic peptides, polyserine, polylysine, and polyglutamic acid show little or no such ability. Polyvaline, however, which has nearly the same hydrophobicity index as poly leucine, failed to lower surface tension or improve adsorption when added to the PL, although the authors propose that this may be due to poor mixing of this particular peptide with the lipids. The data presented in our current study (Table 2) in the production of biologically active pulmonary surfactants. Initial studies showed that the normally dimeric SP-B protein could be reduced and alkylated with the resultant monomeric peptide chains having activity equal to that of the residual dimeric protein after recombination with the phospholipids DPPC and PG (Table I) . It is noteworthy, however, that the activity of the dimer that had undergone the reduction and alkylation procedure but failed to dissociate into separate chains (as analyzed on SDS-PAGE) was less than the activity of untreated SP-B, suggesting that alkylation of one or more of the seven cysteines in this molecule may lower its activity. Attempts No attempt was made in these studies to determine the extent of oligomerization of these cysteine-containing peptides. It is possible that the peptides, although stored under vacuum, when formulated into the synthetic surfactants, may undergo varying amounts of dimerization or larger aggregation. The native SP-B molecule prefers to exist in a dimeric state, although it is unknown which cysteine(s) are involved. Waring et al. (36) , in a recent study utilizing a cysteine-containing SP-B peptide (pl-25) , found the peptide to be present in both monomeric and oligomeric forms, The use of noncysteine-containing analogues of the peptides would allow determination of the role of cysteine in the activities of these peptides, Synthetic surfactants prepared with selected peptides were instilled into the airways of surfactant-deficient fetal rabbits to show the biologic activity of which these samples are capable. Static pressure/volume curves generated 30 min after surfactant instillation indicated a moderate, although significant, increase in compliance for peptides 52-81 and 66-81 and no increase above the values obtained with PL alone with peptide 1-15 (Fig.  4) . Although greater activity might have been seen if a higher concentration of peptide (> 1.5%) had been used in these studies, it is apparent that in vivo activity does not necessarily correspond to that obtained in vitro. Additionally, differential susceptibility to inhibition by proteins present in the airways could contribute to discrepancies between in vitro and in vivo activities. It is surprising, however, that p66-81, which had in vitro activity similar to p66-80 (Table 4) , was fairly active in the fetal rabbit assay. Perhaps different inhibitor susceptibilities are playing a role here as well.
The ability to perform dynamic compliance measurements aided greatly our efforts to determine biologic activity of the various surfactants. The data, examples of which are shown in Figure 5 , show not only the compliance at the end of the experiment, but also the kinetics of the compliance increases. Analysis of the data shows that, although various synthetic peptide surfactants do result in greatly increased lung compliance, the rate of compliance increase is generally slower than that seen with native human surfactant. This may be due to the relatively high degree of saturation in the PL used in these studies. Although the egg PG we used contains approximately 50% unsaturated fatty acids, the PC was all saturated (dipalmitoyl) in contrast with the PC in native human surfactant, which is only 66% disaturated (24) . A very comprehensive analysis of the components required for maximally active synthetic lung surfactants by Tanaka et at. (22) included a requirement for a free, saturated fatty acid, such as palmitic or stearic, in addition to an acidic PL, such as PG. Using the Tanaka lipid mixture, Waring et at. (36) was able to show that SP-B synthetic peptides pl-25 and p49-66 (with norleucine substituted for methionine) associated with and ordered the lipids in a manner similar to native SP-B. Studies are currently underway in our laboratory to investigate the biophysical and physiologic ramifications of varying both the degree oflipid saturation and the inclusion ofFFA into surfactant mixtures based upon synthetic peptides. Such studies, along with the optimization of the peptide to lipid ratio, and analysis of the other variables in the formulation procedure, may lead to a synthetic surfactant having biologic activity equal to, or surpassing, that of human surfactant isolated from amniotic fluid, as well as further our understanding of the mechanism of surfactant function. To investigate the influence of chain length on surfactantinducing capacity, a number of synthetic peptides derived from the carboxy-terminal sequence of SP-B were prepared (Fig. 3) and their abilities to lower the surface tension of a pulsating bubble after reconstitution with PL were tested. The results are shown in Table 3 . The data suggestthat, in this series of peptides, a minimum chain length of approximately 17 residues is necessary. Although the IS-residue peptide in this series (p66-80) did not result in extremely low surface tensions, other IS-residue peptides have been shown to result in surfactants of adequate surface-tension lowering capacity (see Table 2 ). The high density of hydrophilic amino acids, especially the negatively charged aspartic acid, found at the carboxy terminus of SP-B may preclude this five-or six-residue "tail" from participating in the lipid/protein interaction that appears to be necessary for biophysical activity. Thus, the IS-residue peptide 66-80 may only function as a lO-residue peptide in this regard. Aside from an increase in length by two residues, it is possible that p64-80 functions better than p66-80 in lowering surface tension because of the inclusion of the specific residue(s) arginine and/or methionine (residues 64 and 65) at the amino terminus, Peptide 66-80 contains only three highly charged residues, whereas p64-80 contains four. Perhaps this is a critical difference.
The relationship between peptide length and concentration required for surfactant-inducing capacity was studied. Increasing the concentration of peptides :515 residues in length (up to 10%) did not generate greater activity (Table 4 ). In addition, no consistent dose-response relationship between 1 and 10% peptide could be established using peptides of length~17 residues. Per-publication no. 59l5-IMM from the Department ofImmunology Research Institute of Scripps Clinic, La Jolla, CA.
